<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01232127</url>
  </required_header>
  <id_info>
    <org_study_id>AI424-398</org_study_id>
    <secondary_id>2009-016981-95</secondary_id>
    <nct_id>NCT01232127</nct_id>
  </id_info>
  <brief_title>Effects of Famotidine on the Pharmacokinetics of Atazanavir When Coadministered to Participants With HIV Infection</brief_title>
  <official_title>Open-Label, Multiple-Dose, Drug Interaction Study to Assess the Effect of Famotidine on the Pharmacokinetics of Atazanavir in HIV-Infected Subjects Receiving Atazanavir With Ritonavir and Tenofovir</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effects of famotidine, given twice daily, on
      atazanavir administered with ritonavir and tenofovir in HIV-infected participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol was designed to compare the pharmacokinetic parameters of atazanavir
      administered as atazanavir/ritonavir, 400/100 mg once daily (QD), plus famotidine, 20 mg and
      40 mg twice daily, with the parameters found at the usual clinical dose of
      atazanavir/ritonavir, 300/100 mg QD, without famotidine in HIV-infected participants
      receiving tenofovir disoproxil fumarate and at least 1 other nucleoside reverse transcriptase
      inhibitor.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir</measure>
    <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir</measure>
    <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir</measure>
    <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest</measure>
    <time_frame>Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.</time_frame>
    <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Vital Signs</measure>
    <time_frame>Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
    <description>Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</measure>
    <time_frame>Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
    <description>ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett's and Fridericia's formulae), and Investigator-identified ECG abnormalities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormalities in Laboratory Test Results</measure>
    <time_frame>Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
    <description>PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10*3 c/uL): &lt;0.85*PreRx, if PreRx &lt;1.5; &lt;1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): &gt;1.25*PreRx if PreRx &gt;ULN; &gt;1.25*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN. Bilirubin, total (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV</condition>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>FAM=famotidine. The protocol required that participants enrolled in this study already be receiving atazanavir, ritonavir, TDF, and 1 or more NRTIs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsule, oral, 300 mg, once daily, 10 days</description>
    <arm_group_label>Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>BMS-232632</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atazanavir</intervention_name>
    <description>Capsule, oral, 400 mg, once daily, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
    <other_name>Reyataz</other_name>
    <other_name>BMS-232632</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Capsule, oral, 100 mg, once daily, 10 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Capsule, oral, 100 mg, once daily, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir (TDF)</intervention_name>
    <description>Capsule, oral, 300 mg, once daily, 10 days</description>
    <arm_group_label>Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir (TDF)</intervention_name>
    <description>Capsule, oral, 300 mg, once daily, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside Reverse Transcriptase Inhibitor (NRTI)</intervention_name>
    <description>Oral, 10 days</description>
    <arm_group_label>Atazanavir/ritonavir (300/100 mg) + TDF + ≥ 1 NRTI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nucleoside Reverse Transcriptase Inhibitor (NRTI)</intervention_name>
    <description>Oral, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine (FAM)</intervention_name>
    <description>Tablet, oral, 20 mg, twice daily, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (20)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine (FAM)</intervention_name>
    <description>Tablet, oral, 40 mg, twice daily, 7 days</description>
    <arm_group_label>Atazanavir/ritonavir (400/100) + TDF + ≥1 NRTI + FAM (40)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Males and females, 18 to 65 years of age, with HIV infection and a body mass index of
             18.0 to 35.0 kg/m^2

          -  HIV-infected participants receiving a treatment regimen containing only
             atazanavir/ritonavir, 300/100 mg once daily (QD) + tenofovir, 300 mg QD + at least 1
             other nucleotide reverse transcriptase inhibitor continuously for at least 3 months
             prior to study day 1

          -  Plasma HIV RNA levels of &lt;50 copies/mL and a CD4 count &gt;200 cells/mm^3.

          -  No history of virologic failure on a protease inhibitor (PI), documented phenotypic PI
             resistance, or primary PI mutations, according to International AIDS Society
             recommendations

          -  No documented phenotypic resistance to atazanavir or primary genotypic mutations
             causing resistance to atazanavir

          -  Women of childbearing potential who were not nursing or pregnant and were using an
             acceptable method of contraception for at least 4 weeks before dosing, during the
             study, and for 8 weeks from the last dose of study drug.

          -  Women with a negative pregnancy test result within 24 hours prior to dosing with study
             medication

          -  Women not breastfeeding

          -  Men willing or able to agree to practice barrier contraception for the duration of the
             study and at least 3 months after dosing.

        Key exclusion criteria:

          -  Any history of CD4 cell count &lt;50 cells/mm^3

          -  Previously documented phenotypic or genotypic resistance to any of the currently
             prescribed NRTIs

          -  Any significant acute illness within 6 months of study day 1 or chronic medical
             illness unless stable or controlled by a nonprohibited medication

          -  Any major surgery within 4 weeks of study day 1

          -  Any gastrointestinal surgery that could impact upon the absorption of any study drug

          -  Inability to be venipunctured and/or tolerate venous access

          -  History of Gilbert's syndrome, hemophilia, chronic pancreatitis, hypochlorhydria,
             achlorhydria, clinically relevant gastroesophageal reflux disease, hiatal hernia, or
             peptic/gastric ulcer disease

          -  Intractable diarrhea (≥ 6 loose stools/day for at least 7 consecutive days) within 30
             days prior to study day 1

          -  Recent (within 6 months prior to study day 1) drug or alcohol abuse

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, electrocardiogram (ECG)

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, ECG, or clinical laboratory determinations, which
             would not be expected for the extent of HIV disease

          -  Any of the following on 12-lead ECG prior to dosing on study day 1, confirmed by
             repeat: PR ≥ 210 msec; QRS ≥ 120 msec; QT ≥ 500 msec; QTcF ≥ 450 msec

          -  Second- or third-degree A-V block or clinically relevant ECG abnormalities

          -  Positive urine screen for drugs of abuse at screening or prior to dosing without a
             valid prescription. Positive urine drug screen for cannabinoids with or without a
             prescription is not exclusionary

          -  Creatinine clearance, as estimated by method of Cockcroft and Gault, less than 60
             mL/min

          -  Liver enzyme levels &gt; 3* the upper limit of normal (ULN) prior to dosing on study day
             1

          -  Total bilirubin level &gt;10*ULN prior to study day 1

          -  Positive blood screen for hepatitis B surface antigen or hepatitis C antibody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SW10 9NH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2010</study_first_submitted>
  <study_first_submitted_qc>November 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2010</study_first_posted>
  <results_first_submitted>July 23, 2012</results_first_submitted>
  <results_first_submitted_qc>July 25, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 28, 2012</results_first_posted>
  <last_update_submitted>August 27, 2012</last_update_submitted>
  <last_update_submitted_qc>August 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Atazanavir Sulfate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
          <description>Participants received atazanavir/ritonavir, 300/100 mg QD, plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI). Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
        </group>
        <group group_id="P2">
          <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
          <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg BID. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
        </group>
        <group group_id="P3">
          <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
          <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1: Days 1-10</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25">Participants who received treatment.</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Discontinued due to dosing error</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2: Days 11-17</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24">Participants who received treatment.</participants>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3: Days 18-24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="24">Participants who received treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Treated</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Younger than 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65 years and older</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.8" lower_limit="23" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Absolute Count</title>
          <description>n=23 (n=evaluable participants)</description>
          <units>Cells/μL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="584.8" spread="194.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4 Percent of Total</title>
          <description>n=23 (n=evaluable participants)For 2 participants, baseline CD4 percent total and absolute count were performed as an unscheduled visit after the initial screening visit and thus, are not included in this summary.</description>
          <units>Percent of participants</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="7.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest</title>
        <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
        <time_frame>Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
            <description>Participants received atazanavir/ritonavir, 300/100 mg QD, plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI) on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg BID on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O3">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Death as Outcome, Serious Adverse Events (SAEs), Adverse Events (AEs) Leading to Discontinuation, AES, and AEs of Clinical Interest</title>
          <description>An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization.</description>
          <population>Participants who received study drug and were evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of clinical interest: Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AEs of clinical interest: Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Vital Signs</title>
        <description>Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.</description>
        <time_frame>Days 1, 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated</title>
            <description>All participants who received at least 1 dose of atazanavir with ritonavir and tenofovir and with or without famotidine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Vital Signs</title>
          <description>Vital signs include temperature, respiratory rate, seated blood pressure, and heart rate.</description>
          <population>Participants who received study drug and were evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Isolated decrease in heart rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sporadic respiration rate &gt;16 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir</title>
        <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
            <description>Participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI)on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg twice daily (BID) on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O3">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Plasma Concentration (Cmax) and Trough Observed Plasma Concentration (Ctrough) for Atazanavir and Ritonavir</title>
          <population>Participants who received study drug and had adequate PK profiles.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atazanavir Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3512" spread="35.4"/>
                    <measurement group_id="O2" value="4131" spread="37.7"/>
                    <measurement group_id="O3" value="3322" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Atazanavir Ctrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="496" spread="50.9"/>
                    <measurement group_id="O2" value="602" spread="60.3"/>
                    <measurement group_id="O3" value="494" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1141" spread="30.5"/>
                    <measurement group_id="O2" value="1148" spread="29.8"/>
                    <measurement group_id="O3" value="1096" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir Ctrough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.8" spread="58.7"/>
                    <measurement group_id="O2" value="49.2" spread="66.8"/>
                    <measurement group_id="O3" value="47.3" spread="53.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir</title>
        <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
            <description>Participants received atazanavir/ritonavir, 300/100 mg QD, plus TDF, 300 mg QD, and at least 1 NRTI on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg BID on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O3">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
        </group_list>
        <measure>
          <title>Time of Maximum Observed Plasma Concentration (Tmax) for Atazanavir and Ritonavir</title>
          <population>Participants who received study drug and had adequate PK profiles.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atazanavir Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.0" upper_limit="4.0"/>
                    <measurement group_id="O3" value="3.0" lower_limit="2.0" upper_limit="4.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir Tmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="2.0" upper_limit="4.2"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.0" upper_limit="6.0"/>
                    <measurement group_id="O3" value="4.0" lower_limit="2.0" upper_limit="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir</title>
        <time_frame>Days 10, 11, 17, 18, 24, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and had adequate PK profiles.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
            <description>Participants received atazanavir/ritonavir, 300/100 mg QD, plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI) on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg BID on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O3">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve in 1 Dosing Interval (Time 0 to 24 Hours Postdose) (AUC[TAU]) for Atazanavir and Ritonavir</title>
          <population>Participants who received study drug and had adequate PK profiles.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Atazanavir AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32562" spread="37.7"/>
                    <measurement group_id="O2" value="37894" spread="40.7"/>
                    <measurement group_id="O3" value="31481" spread="48.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ritonavir AUC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7317" spread="35.6"/>
                    <measurement group_id="O2" value="7430" spread="32.4"/>
                    <measurement group_id="O3" value="7052" spread="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</title>
        <description>ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett’s and Fridericia’s formulae), and Investigator-identified ECG abnormalities.</description>
        <time_frame>Days 1 and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>All Treated</title>
            <description>All participants who received at least 1 dose of atazanavir with ritonavir and tenofovir and with or without famotidine.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Electrocardiogram (ECG) Findings</title>
          <description>ECG findings include heart rate, ECG intervals (including PR, QRS, QT, and corrections to QT using both Bazett’s and Fridericia’s formulae), and Investigator-identified ECG abnormalities.</description>
          <population>Participants who received study drug and were evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nonspecific ST/T wave abnormality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Short PR interval</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormalities in Laboratory Test Results</title>
        <description>PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10*3 c/uL): &lt;0.85*PreRx, if PreRx &lt;1.5; &lt;1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): &gt;1.25*PreRx if PreRx &gt;ULN; &gt;1.25*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN. Bilirubin, total (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN.</description>
        <time_frame>Days 11, 18, and 25 (end of study) and at study discharge for those who discontinued prematurely.</time_frame>
        <population>Participants who received study drug and were evaluable.</population>
        <group_list>
          <group group_id="O1">
            <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
            <description>Participants received atazanavir/ritonavir, 300/100 mg QD, plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI) on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O2">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg BID on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
          <group group_id="O3">
            <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
            <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormalities in Laboratory Test Results</title>
          <description>PreRX=pretreatment; ULN=upper limit of normal. Neutrophils, (absolute), low (10*3 c/uL): &lt;0.85*PreRx, if PreRx &lt;1.5; &lt;1.5 if PreRx ≥1.5. Alanine aminotransferase, high (U/L): &gt;1.25*PreRx if PreRx &gt;ULN; &gt;1.25*ULN if PreRx ≤ULN. Bilirubin, direct (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN. Bilirubin, total (mg/dL), high: &gt;1.1*ULN if PreRx ≤ULN;&gt; 1.1*ULN if PreRx is missing; &gt;1.25*PreRx if PreRx &gt;ULN.</description>
          <population>Participants who received study drug and were evaluable.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WBC differential count (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neutrophils (absolute) (low)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine aminotransferase (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate aminotransferase (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, direct (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bilirubin, total (high)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Days 1 through 25 (end of study), continuously, and at study discharge for those who discontinued prematurely.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atazanavir/Ritonavir (300/100) + TDF + ≥NRTI</title>
          <description>Participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus tenofovir (TDF), 300 mg QD, and at least 1 nucleoside reverse transcriptase inhibitor (NRTI) on Days 1 through 10. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
        </group>
        <group group_id="E2">
          <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (20)</title>
          <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 20 mg twice daily (BID) on Days 11 through 17. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF.</description>
        </group>
        <group group_id="E3">
          <title>Atazanavir/Ritonavir (400/100) + TDF + ≥NRTI + Famotidine (40)</title>
          <description>Participants received atazanavir/ritonavir, 400/100 mg QD, plus TDF, 300 mg QD, plus at least 1 NRTI, plus famotidine, 40 mg BID on Days 18 through 24. Atazanavir/ritonavir and TDF were administered with food. The AM dose of famotidine was administered simultaneously with atazanavir/ritonavir/TDF</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BMS Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

